Clarivate Analytics have created the Multiple Sclerosis Disease report, which provides an up-to-date assessment of the disease landscape, including its market size, an overview of the burden for clinical development, the competitive intensity of the current and future market, and its unmet medical needs.
Multiple sclerosis (MS) is a young onset, chronic, inflammatory, demyelinating disease of the central nervous system (CNS) resulting in the accumulation of irreversible disabilities such as muscle weakness, visual disturbances and other neurological impairments. There is no available cure although existing therapies can relieve symptoms, delay disease progression and reduce the number of relapses. For many years, interferon were the only MS drugs prescribed as first-line therapies, although this paradigm is changing because emerging therapies have demonstrated less adverse events than interferons. The report also presents an overview of the treatment algorithms in place, as well as the next generation of MS therapies following on from the recent launch of ocrelizumab.
The report includes Clarivate?s proprietary patient population forecast built around the company?s Incidence & Prevalence Database, focusing on the US, the 5EU countries, Japan, and BRIC. Clarivate Analytics? analysts also provide their opinions on rising stars in the development landscape, as well as promising mechanisms of interest.
Executive summary
1. Disease background
2. Market size
2.1 Epidemiology
2.2 Financial
3. Clinical feasibility
3.1 Biomarkers
3.2 Preclinical models
3.3 Clinical trial overview
4. Competitive Landscape
4.1 Standards of care algorithms
4.2 Unmet Needs
5. Development Landscape
5.1 Pipeline
5.2 Key players
5.3 Promising MOAs
6. Appendix
| File Size : | 1
file
, 1.8 MB |
| Number of Pages : | 53 |
| Published : | 12/01/2018 |
